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Abstract. The present study aimed to evaluate the similar 
survival benefits of a good response [complete response or 
partial response (CR/PR)] and stable disease (SD) to chemo-
therapy in non‑small cell lung cancer (NSCLC) patients in 
clinical practice. All 322 patients who were treated between 
1999 and 2012 with first‑line platinum‑based chemotherapy 
were retrospectively analyzed. Tumor responses were clas-
sified according to the response evaluation criteria for solid 
tumors. A total of 67 (20.8%) patients experienced CR/PR 
and 165 (51.2%) achieved SD. There was no difference in 
progression‑free survival between the patients with CR/PR 
and those with SD (P=0.347). There was also no difference 
between the two groups with regard to overall survival time 
(P=0.878). In multivariate analysis, disease‑control (more than 
SD) was one of the favorable prognostic factors. In clinical 
practice, a survival benefit would be provided not only for the 
patients who have good response, but also for those with SD.
Introduction
The incidence and mortality rates of lung cancer have 
increased globally during the last few decades (1,2). The 
majority of cases of lung cancer diagnosed were non‑small 
cell lung cancer (NSCLC), and ~40% of patients with NSCLC 
are affected by advanced diseases (3). For patients with 
advanced NSCLC with a good performance status, systemic 
chemotherapy is the standard therapy at present. The first‑line 
treatment for such patients is platinum‑based chemotherapy, 
which improves symptom control, quality of life and survival 
as compared with best supportive care (4). A good response 
[complete response or partial response (CR/PR)] to chemo-
therapy has typically been equated with the clinical benefit of 
increased survival (5), but only 20‑30% of patients achieve a 
good response in previous clinical trials, while 40‑50% main-
tain a stable disease (SD) status (6‑8). Certain previous studies 
reported that an initial good response and stable disease indi-
cate similar survival benefits for chemotherapeutical patients 
with advanced NSCLC (9,10). The present retrospective study 
was undertaken to evaluate the similar survival benefits of a 
good response and stable disease to platinum‑based chemo-
therapy in previously untreated NSCLC patients.
Patients and methods
Patients. The patients enrolled in the present study were 
those consecutively diagnosed with NSCLC and treated 
with platinum‑based chemotherapy as first‑line treatment at 
the University of Tsukuba Hospital and Tsukuba Medical 
Center Hospital (both Tsukuba, Ibaraki, Japan) between 
January 1999 and December 2012. All the patients were histo-
logically/cytologically confirmed as presenting with NSCLC 
and unresectable advanced disease. The histopathological 
diagnosis was defined by the World Health Organization 
classification (11), and patients were staged according to the 
Union for International Cancer Control tumor‑node‑metas-
tasis system (12).
Treatment and response. Enrolled patients received at least 
one cycle of cisplatin‑ or carboplatin‑based chemotherapy. 
The clinical, pathological and radiological data, and the 
follow‑up information obtained until May 2013 were retro-
spectively reviewed. The patient characteristics and efficacy 
were evaluated using patient data extracted from the database. 
Tumor responses were classified as a CR, PR, SD, progressive 
disease (PD) or not evaluable (NE), according to the response 
evaluation criteria for solid tumors (RECIST) version 1.1 (13). 
This observational study conformed to the Ethical Guidelines 
for Clinical Studies issued by the Ministry of Health, Labor 
and Welfare of Japan.
The progression‑free survival (PFS) time of each patient was 
calculated from the day that chemotherapy was commenced 
until disease progression. Overall survival (OS) time was 
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calculated from the day that chemotherapy was commenced 
until mortality or the latest follow‑up of the patient. 
Statistical analysis. The survival rate was analyzed by the 
Kaplan‑Meier method, and comparisons were performed 
using the log‑rank test in univariate analysis. Significant vari-
ables identified in the univariate analysis were included in the 
multivariate survival analysis using Cox proportional hazards 
model to study the effects of clinicopathological factors on 
survival. P<0.05 was considered to indicate a statistically 
significant difference. All statistical analyses were performed 
using StatView software for Windows, version 5.0 (SAS Insti-
tute Inc., Cary, NC, USA).
Results
Patients. Between January 1999 and December 2012, 
322 patients were diagnosed with advanced NSCLC and received 
platinum‑based chemotherapy at two hospitals. The median 
follow‑up period was 10.2 months (range, 0.7‑134.0 months). 
Table I shows the patient characteristics. Of the 322 patients, 
234 were male, and the median age was 64 years 
(range, 21‑88 years). In total, 85 patients were never‑smokers. 
With regard to performance status (PS), 258 patients exhibited 
a PS of 0‑1 and 64 exhibited a PS of 2‑4. Overall, 33 patients 
presented with stage IIIA‑B disease and 289 patients with 
stage IV. Of the 322 NSCLC cases, 246 (76.4%) were adeno-
carcinoma, 62 (19.3%) were squamous cell carcinoma, 11 
(3.4%) were large cell carcinoma, and 3 (0.9%) were other 
types. Epidermal growth factor receptor (EGFR) mutation 
positivity was found in 19 patients, while 69 patients were 
negative for the mutation and 234 patients were not evaluated 
for EGFR. The chemotherapy regimens used are presented in 
Table II; 105 (32.6%) patients were administered cisplatin‑based 
chemotherapy, and 217 (67.4%) patients were administered 
carboplatin‑based chemotherapy as first‑line treatment. In the 
platinum‑based chemotherapy regimens [carboplatin (area under 
the serum concentration‑time curve, 4‑5 mg/ml/min; day 1; 
3‑4‑week cycle) and cisplatin (60‑80 mg/m2; day 1, 3‑4‑week 
cycle)], the cytotoxic drugs such as paclitaxel (180‑200 mg/m2; 
day 1; 3‑4‑week cycle), doctaxel (60 mg/m2; day 1; 3‑4‑week 
cycle), gemcitabine (1000 mg/m2; days 1 and 8; 3‑4‑week 
cycle) and pemetrexed (500 mg/m2; day 1; 3‑4‑week cycle) 
were administered in 95, 62, 47 and 43 patients, respectively. 
The median number of cycles of platinum‑based chemotherapy 
was 2 (range, 1‑7 cycles), and the median number of cycles of 
maintenance therapy was 3 (range, 1‑12 cycles).
Response/disease control and survival. The median OS time 
for the 322 patients was 11.7 months. A total of 67 (20.8%) 
patients were responders (no CR and 67 PR) and 165 (51.2%) 
patients achieved SD, which amounted to a disease control rate 
(DCR) of 72.0%. In the 260 patients with non‑squamous cell 
carcinoma, 50 (19.2%) were responders (no CR and 50 PR) and 
135 (51.9%) achieved SD, which amounted to a DCR of 71.1%. 
In the 62 patients with squamous cell carcinoma, 17 (27.4%) 
were responders (no CR and 17 PR) and 30 (48.4%) patients 
achieved SD, which amounted to a DCR of 75.8%.
As shown in Fig. 1, the median OS time in the 232 patients 
with CR/PR or SD was better than that of the 90 patients with 
PD (14.6 vs. 5.1 months; P<0.001). By contrast, there was no 
difference in PFS time between the 67 patients with CR/PR 
and the 165 patients with SD (6.8 vs. 5.5 months; P=0.347) 
(Fig. 2). There was also no significant difference between 
patients with CR/PR and those with SD with regard to OS time 
(15.6 vs. 14.3 months; P=0.878) (Fig. 3).
In the patients with non‑squamous cell carcinoma, the 
median OS time in the patients with CR/PR and SD was better 
than that in the patients with PD (16.1 vs. 5.2 months; P<0.001). 
There was no difference in PFS time between the patients with 
CR/PR and the patients with SD (7.3 vs. 5.7 months; P=0.253). 
Additionally, there was no significant difference between the 
patients with CR/PR and those with SD with regard to OS 
(16.9 vs. 15.1 months; P=0.938).
In the patients with squamous cell carcinoma, the OS 
time in the patients with CR/PR and SD was better than 
that in the patients with PD (13.1 vs. 4.8 months; P<0.001). 
There was no difference in PFS time between the patients 
with CR/PR and the patients with SD (5.0 vs. 5.1 months; 
P=0.978). Also, there was no significant difference between 
the patients with CR/PR and those with SD with regard to OS 
time (13.1 vs. 13.3 months; P=0.732).
Prognostic factors. Next, the prognostic factors of the 
322 NSCLC patients were evaluated. Table III presents the 
results of the univariate and multivariate analyses. In the 
Table I. Characteristics of 322 patients with non‑small cell 
lung cancer who received platinum‑based chemotherapy.
Characteristic Value
Median age (range), years 64 (21‑88)
Gender, n (%)
  Male 234 (72.7)
  Female   88 (27.3)
Smoking status, n (%)
  Smoker 237 (73.6)
  Never‑smoker   85 (26.4)
Performance status, n (%)
  0‑1 258 (80.1)
  2‑4   64 (19.9)
Clinical stage, n (%)
  IIIA‑B   33 (10.2)
  IV 289 (89.8)
Pathology, n (%)
  Adenocarcinoma 246 (76.4)
  Squamous cell carcinoma   62 (19.3)
  Large cell carcinoma 11 (3.4)
  Other   3 (0.9)
EGFR mutation, n (%)
  Positive 19 (5.9)
  Negative   69 (21.4)
  Not evaluated 234 (72.7)
EGFR, epidermal growth factor receptor.
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univariate analysis, the female gender, a good PS (PS of 
0‑1), never‑smoker status, non‑squamous cell carcinoma, 
cisplatin‑based chemotherapy, pemetrexed‑containing 
chemotherapy, bevacizumab‑containing chemotherapy and 
disease‑controlled patients (CR/PR and SD) were associ-
ated with a longer OS time. According to the multivariate 
Cox proportional hazards model, a good PS (PS of 0‑1), 
never‑smoker status, pemetrexed‑containing chemotherapy 
and disease‑controlled patients (CR/PR and SD) were favor-
able prognostic factors.
Discussion
In the present study evaluating daily practice in NSCLC 
patients, four main results were found. First, in the overall 
group of NSCLC patients, the DCR (CR/PR and SD rates) 
was 72.0%, although the response rate that was composed 
of CR/PR alone was only 20.8%. Second, the OS time was 
11.7 months in the overall group of NSCLC patients, and 
14.6 months in the disease‑controlled patients (patients with 
CR, PR and SD). Third, the OS time in the disease‑controlled 
patients was longer than that in the patients with PD, but 
there was no statistical significant difference in the OS time 
between the patients with CR/PR and those with SD. The 
same results were observed in the patients with squamous 
cell lung carcinoma and those with non‑squamous cell carci-
noma. Fourth, the OS time in the disease‑controlled patients 
treated with platinum and pemetrexed was 21.4 months.
Thus, these results illustrated that prolongation of 
survival time was associated not with the response rate, 
but with the disease control rate, and a high response rate 
may have scarce clinical meaning in daily practice. If a cure 
would not be achieved, these results implied that it would be 
Table II. Regimens of chemotherapy.
Regimen Value
Platinum, n (%)
  Cisplatin 105 (32.6)
  Carboplatin 217 (67.4)
Combined drugs, n (%)
  Paclitaxel   95 (29.5)
  Docetaxel   62 (19.3)
  Gemcitabine   47 (14.6)
  Pemetrexed   43 (13.4)
  Vinorelbine   38 (11.8)
  S‑1 13 (4.0)
  Etoposide 12 (3.7)
  Vindesine 11 (3.4)
  Bevacizumab 11 (3.4)
  Irinotecan   3 (0.9)
Median number of platinum‑based   2 (1‑7)
chemotherapy cycles (range)
Median number of maintenance     3 (1‑12)
therapy cycles (range)
Figure 1. OS in non‑small cell lung cancer patients with a CR/PR/SD or 
PD. Patients with CR/PR/SD had a significantly better prognosis com-
pared with patients with PD (median OS, 14.6 vs. 5.1 months; P<0.001). 
OS, overall survival; CR, complete response; PR, partial response; SD, 
stable disease; PD, progressive disease.
Figure 2. PFS in non‑small cell lung cancer patients with CR/PR or SD. 
No significant difference was identified between the patients with CR/PR 
and SD (median PFS, 6.8 vs. 5.5 months; P=0.347). PFS, progression‑free 
survival; CR, complete response; PR, partial response; SD, stable disease.
Figure 3. OS in non‑small cell lung cancer patients patient with CR/PR or 
SD. No significant difference was identified between patients with CR/PR 
and SD (median OS, 15.6 months vs. 14.3 months, P=0.878). OS, overall 
survival; CR, complete response; PR, partial response; SD, stable disease.
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important not to merely achieve shrinkage of the tumor, but 
to maintain the patent's condition for a long time without any 
tumor progression.
In previous studies, there have been various opinions with 
regard to the survival of patients with SD; certain studies have 
insisted that patients with SD were associated with a favorable, 
long OS time compared with those with CR/PR (9,10), and 
another study described a longer OS time obtained in patients 
with CR/PR compared with those with SD (14). Lara et al (9) 
suggested that patients who achieved SD at 8 weeks experi-
ence a survival time equal to that of PR/CR patients. The study 
claimed that DCR (CR, PR and SD) is stronger than response 
(CR/PR alone) in the prediction of the OS time of patients with 
advanced NSCLC. He et al (10) reported that initial CR/PR 
and SD result in similar PFS and OS times for patients with 
advanced NSCLC receiving platinum‑based chemotherapy. 
One previous study suggested that SD may be representative 
of a potential survival benefit of chemotherapy. Therefore, 
the differentiation between SD and CR/PR may not be of 
any practical importance (15). By contrast, Coudert et al (14) 
reported that SD after first‑line chemotherapy was a signifi-
cant negative prognostic factor compared with CR/PR. 
Recently, Mandrekar et al (16) indicated that patients with 
PD experienced worse survival compared with those with 
non‑PD, with a certain degree of separation between the 
NSCLC categories of SD and CR/PR. Controversy remains 
with regard to whether initial CR/PR and SD indicate similar 
survival benefits or not in advanced NSCLC patients receiving 
chemotherapy. This may be due to the complexity of SD that 
exhibits minor increases and decreases: When SD is achieved, 
some patients experience tumor shrinkage of <30% in the 
diameter of the target lesions, whilst others experience tumor 
increases of <20% in the diameter of the target lesions. These 
'decreased' SD and 'increased' SD may have different behavior. 
In the present patients, there was no statistical significant 
difference in survival time between the patients with SD and 
those with CR/PR.
In clinical trials and in practice, prolongation of survival 
time appears to have been recorded in NSCLC patients in 
recent years, which may have been due to the appearance of 
more effective and less toxic drugs (17), molecular targeting 
agents (18‑22) and the improvement of supportive therapy, 
such as G‑CSF (23) and antiemetic drugs (24). In the present 
study, the survival of all consecutive NSCLC patients in daily 
Table III. Prognostic factors of the 322 non‑small cell lung cancer patients.
A, Univariate survival analysis (log‑rank test)
Prognostic factors Median OS time, months P‑value
Gender (female/male) 16.7/10.9 <0.001
Age, years (<70/≥70) 11.2/13.3 0.528
PS (0-1/2‑4) 13.6/5.8 <0.001
Smoking status (never‑smoker/smoker) 18.1/11.0 <0.001
Non‑squamous/squamous cell carcinoma 12.3/10.5 0.046
CDDP/CBDCA 13.5/11.4 0.041
PEM (+/‑) 21.4/10.2 <0.001
Bevacizumab (+/‑) 21.4/11.3 0.004
Maintenance (+/‑) 18.1/11.6 0.191
CR+PR/SD+PD 15.6/11.2 0.064
CR+PR+SD/PD 14.6/5.1 <0.001
B, Multivariate analysis (Cox's proportional hazards model)
Prognostic factors Hazard ratio 95% CI P‑value
Female 0.75 0.52‑1.07 0.106
PS 0‑1 0.48 0.35‑0.66 <0.001
Never‑smoker 0.64 0.44‑0.93 0.020
Non‑squamous cell carcinoma 0.98 0.71‑1.36 0.896
CDDP 0.95 0.71‑1.27 0.722
PEM 0.47 0.32‑0.68 <0.001
Bevacizumab 0.60 0.32‑1.14 0.117
CR+PR+SD 0.37 0.28‑0.48 <0.001
CDDP, cisplatin; CBDCA, carboplatin; PEM, pemetrexed; CR, complete response; PR, partial response; SD, stable disease; PD, progressive 
disease; CI, confidence interval.
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practice was evaluated, therefore, the study included ʻunfitʼ 
patients, who are usually excluded from clinical trials. 
However, it was notable that the OS time in these patients was 
not shorter than that observed in recent clinical trials (25‑30). 
In addition, in the present patients treated with platinum and 
pemetrexed, the OS time was as long as that observed in the 
PARAMOUNT trial (16.9 months) (31). In patients treated 
with bevacizumab and those with maintenance therapy with 
the drug, the OS time in the present study was evaluated to 
be as good as that of previous clinical trials (32‑33). Our 
ʻdaily clinical practiceʼ results provide information for the 
near future treatment of NSCLC patients. We believe that 
these favorable results are largely dependent on the power of 
novel antitumor drugs, such as pemetrexed, tyrosine kinase 
inhibitors and bevacizumab.
Despite these significant findings, the present study has 
certain limitations. The first limitation was inherent to the 
retrospective design of the study: lead time and length time 
biases could not be avoided. Second, OS time may have been 
affected by other factors, such as the effects of second‑line 
and subsequent therapies. Third, the study period was so long 
that various regimens were enrolled. Not only novel antitumor 
drugs, but also improvements in supportive care and advances 
in imaging techniques may have conferred favorable effects 
for the survival of patients in recent years. Fourth, the 
RECIST criteria were not always applied to clinical chemo-
therapy decisions in daily practice. If SD is achieved in daily 
practice, careful consideration is required to decide whether 
or not to continue the chemotherapy using the same regimen.
Regardless of these limitations, the findings of the present 
study have certain clinical significance for the management 
of future NSCLC patients of unselected groups. The results 
confirmed that careful consideration is required in treating 
NSCLC patients who experience SD with chemotherapy.
In conclusion, if the primary outcome of chemotherapy 
for NSCLC at present is not shrinkage of the tumor, but is 
the prolongation of survival, chemotherapy would provide 
a clinical benefit not only for the 20% of patients with a 
good response who have CR/PR, but also for the 70% of 
disease‑controlled patients who have SD, PR and CR.
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